Mountain rescue team help injured walker on Scafell Pike in Lake District
The walker was unable to continue his journey on Scafell Pike, and Wasdale Mountain Rescue were brought in to assist him.
The team was called out on Wednesday, June 18, to the incident.
In a post on social media, Wasdale Mountain Rescue said: "The team was called on Wednesday afternoon by Cumbria Police.
"A walker had fallen and painfully injured his knee, making it impossible to continue further. He has also lost consciousness briefly but has since recovered.
"A full callout was made, and the team made their way to the location. Helimed 58 also responded but was unable to land close enough, so it was forced to abort.
"A medical assessment was made before transferring the walker carefully into the team stretcher.
"The long but routine carry was then completed without incident down to Brackenclose, where the walker was transferred into their own vehicle for onward transfer to the hospital.
"We wish the walker a very quick recovery and hope to see him back on the fells soon."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
More mothers to get 24/7 access to breastfeeding support
More new mothers will be able to access 24/7 breastfeeding support after the Government extended a national helpline. The National Breastfeeding Helpline provides free, evidence-based information day and night – supporting families to overcome challenges that might prevent mothers from successfully breastfeeding their baby. Breastfeeding can take time to establish, with some mothers worrying if their baby is feeding well enough, particularly in the days after birth. Public health minister Ashley Dalton said: 'Many parents will know the struggle of being up in the middle of the night, desperately trying anything to get your baby to feed. 'It can be incredibly overwhelming and deeply lonely. 'We are determined to make sure more women get the support they need through this vital 24/7 helpline.' Data published by the Office for Health Improvement and Disparities (OHID) in November shows the prevalence of breastfeeding at six to eight weeks in England increased to 52.7% in 2023-24 compared with 49.2% in 2022-23. At the time, OHID said breastfeeding rates 'are generally improving at local level in England'. However, there are disparities, with women in wealthier areas more likely to breastfeed than those in more deprived areas. Catherine Hine, chief executive of The Breastfeeding Network – which runs the helpline alongside the Association of Breastfeeding Mothers, said: 'While some callers seek help for a wider range of infant feeding challenges, we know that almost nine in 10 (89%) of callers are more confident to continue breastfeeding after contacting the helpline. 'Many women also call to talk about combination feeding, introducing solids, stopping breastfeeding and formula feeding. 'We're really excited that shifting to a 24-hour service has been so popular and that our great team are being contacted by women and families throughout the UK and with a wide variety of backgrounds and infant feeding experiences.' Minister for children and families Janet Daby said extending the helpline for 2025/26 is 'just one part of a much bigger effort to transform how families are supported'. The move forms part of wider reforms of family services, backed by £126 million in funding that will support the Family Hubs and Start for Life programme. This includes £18.5 million to improve infant feeding across 75 local authorities in England. Ms Dalton added: 'Through our Plan for Change, we're going further to ensure every child gets the best start in life. 'We've provided extra funding for local infant feeding services through the Family Hubs and Start for Life programme, where parents can access drop-in sessions for practical and emotional support.' Earlier this month, the Government also announced there will be a Best Start family hub in every local authority in England by April 2026, with £500 million targeted at disadvantaged communities. The service has been described as a 'one-stop shop' for families with children from pregnancy through to early years and beyond.
Fast Company
8 hours ago
- Fast Company
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022. The High Court also ruled that the other Moderna patent under challenge in the case was invalid. Moderna was refused permission to appeal against that decision. But Pfizer and BioNTech were granted permission to appeal in an attempt to try and invalidate Moderna's second patent and appealed earlier this month, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid. Judge Richard Arnold, however, rejected Pfizer and BioNTech's appeal. Pfizer and BioNTech said in a joint statement that the decision 'does not change our unwavering stance that this patent is invalid' and the companies will seek to appeal. 'This decision has no immediate impact on Pfizer and BioNTech or Comirnaty,' the companies added. Moderna did not immediately respond to a request for comment. Friday's decision in the latest ruling in the legal dispute between the two sides over their competing vaccines, which helped save millions of lives during the pandemic. The companies have also been involved in proceedings in Germany – where a court ruled in Moderna's favour in March – the United States Patent Office, which held that two Moderna COVID-19 vaccine patents were invalid, and elsewhere.
Medscape
8 hours ago
- Medscape
Chemotherapy Linked to Brain Atrophy in Breast
Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new findings from a pilot study suggested. Memory problems in patients with cancer may not stem solely from stress or anxiety related to their diagnosis but could reflect underlying changes in brain structure, study investigator Paul Edison, PhD, MPhil, professor of neuroscience and clinical professor of neurology at Imperial College London, London, England, told Medscape Medical News . While the findings suggest that chemotherapy may contribute to neuronal damage, the researchers noted that many aspects of the relationship between treatment and brain changes remain unclear. Edison highlighted three key areas that require further investigation — uncovering the mechanisms driving brain atrophy, determining the proportion of patients affected, and identifying effective prevention strategies. Another investigator on the study, Laura Kenny, MD, PhD, associate professor and consultant medical oncologist at Imperial College London, noted that the issue has received limited attention to date but expressed hope that the findings will raise awareness and encourage further research, given its clinical importance. The findings were presented on July 29 at the Alzheimer's Association International Conference (AAIC) 2025. Investigating Cognitive Impact Advances in chemotherapeutic agents have improved survival rates in patients with cancer. However, challenges persist regarding the long-term impact of these drugs. Chemotherapy-associated cognitive impairment, often referred to as 'brain fog' or 'chemobrain,' affects approximately one third of patients with breast cancer following treatment. While cognitive decline resolves within 12 months for some patients, others experience persistent effects that may elevate the risk for neurodegenerative conditions, Edison explained. To evaluate the impact of chemotherapy on the brain, investigators studied 328 women with nonmetastatic breast cancer who had undergone chemotherapy within the past 12 months. Patients received either anthracycline — a drug derived from the Streptomyces peucetius bacterium — or taxanes such as docetaxel and paclitaxel, both commonly used in breast cancer treatment, or a combination of these agents. In addition, some patients may also have had hormone therapy at some point during treatment, said Kenny. Participants completed neurocognitive prescreening tests every 3 months using a specialized artificial intelligence-driven platform, allowing them to take detailed memory assessments online from home. Among those prescreened, 18 individuals with lower neurocognitive scores (mean age, approximately 55 years) and 19 cognitively normal control individuals without breast cancer (mean age, approximately 67 years) underwent comprehensive, in-person, neurocognitive evaluations and MRI scans. Researchers analyzed the scans using region of interest (ROI) and voxel-based morphometry (VBM), which uses sophisticated computer software, to assess grey matter volumes and surface areas. The ROI analysis revealed significant reductions in gray matter volume (measured in mm3) and surface area (measured in mm2) among patients experiencing chemobrain, particularly affecting the isthmus cingulate and pars opercularis, with changes extending into the orbitofrontal and temporal regions. Significant Atrophy The VBM analysis confirmed significant atrophy in the frontal, parietal, and cingulate regions of patients with chemobrain compared with control individuals ( P < .05). Edison noted that this pattern overlaps with brain changes typically observed in Alzheimer's disease and vascular cognitive impairment. For both analyses, 'we demonstrated there is some amount of shrinkage in the brain among patients with chemobrain.' he said. 'The fact that controls are older means the results are even more significant as there's more brain atrophy as people age.' Some of the affected brain regions may be linked to impaired memory, a hallmark of Alzheimer's disease, but Edison cautioned that given the small sample size this finding should be interpreted with caution. While the analysis demonstrated overall lower brain volumes in patients with 'chemobrain' compared with controls, Edison emphasized that this finding reflects a single time point and does not indicate brain shrinkage over time. Other events, including stroke — can also cause brain changes. Edison highlighted the importance of determining the significance of these brain changes, how they affect patients and whether they can be prevented. In-person neurocognitive testing revealed significantly reduced semantic and verbal fluency, as well as lower Mini-Mental State Examination scores in patients with chemobrain. Edison noted that these results support the MRI findings. The team plans to follow patients to track brain changes and memory recovery, Kenny said. While patients with breast cancer are a common focus, the researchers intend to expand the study to other cancers in both men and women, said Kenny. Anecdotally, many patients report memory problems during chemotherapy, she added. Based on discussions with her oncology colleagues, Kenny noted that many patients anecdotally report experiencing memory problems during chemotherapy. More Research Needed Commenting for Medscape Medical News , Rebecca M. Edelmayer, PhD, vice president, Scientific Engagement, at the Alzheimer's Association, said the research may help shed light on why women are more likely to develop dementia than men. For years now, experts have been trying to figure out what puts women at higher risk for AD and other dementias, said Edelmayer. 'We still don't understand whether this involves biologically driven risk factors or socially driven risk factors.' Research linking treatments for other health conditions to increased memory problems may offer some clues, she noted, suggesting a potential avenue for further investigation into the intersection of chemotherapy and neurodegenerative diseases such as Alzheimer's. However, Edelmayer emphasized that this line of research is still in its infancy. Much more work is needed to determine whether there is a direct cause-and-effect relationship with specific chemotherapy drugs, and whether some patients may already be predisposed or at higher risk for cognitive decline, she said. Also commenting for Medscape Medical News , Eric Brown, MD, associate scientist and associate chief of geriatric psychiatry at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada, raised concerns about the study's design. One issue, he noted, is that the researchers did not image all patients who received chemotherapy but instead selected those with the most significant cognitive impairment. As a result, the findings may not have reflected outcomes in the average post-chemotherapy patients but rather represent the most severely affected subgroup. Brown also pointed out that the study did not clarify whether this subgroup had comorbid conditions. It's possible, he said, that some individuals may have had Alzheimer's disease or other forms of dementia unrelated to chemotherapy. He agreed that tracking longitudinal changes in both cognitive scores and neuroimaging — comparing patients who receive chemotherapy with those who do not — would be a valuable next step.
